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Since CKD-712 has been developed as an anti-inflammatory 
agent, we examined the effect of CKD-712 during TLR4 
signaling. Using HEK293 cells expressing TLR4, CKD-712 
was pre-treated 1 hr before LPS stimulation. Activation of 
NF-κB was assessed by promoter assay. The activation of 
ERK, JNK, p38, IRF3 and Akt was measured by western 
blotting. CKD-712 inhibited the NF-κB signaling triggered 
by LPS. The activation of ERK, JNK, p38 or IRF3 was not in-
hibited by CKD-712. On the contrary the activation of these 
molecules was augmented slightly. The activation of Akt with 
stimulation of LPS was also enhanced with CKD-712 
pre-treatment at lower concentration, but was inhibited at 
higher concentration. We suggest that during TLR4 signaling 
CKD-712 inhibits NF-κB activation. However, CKD-712 
augmented the activation of Akt as well as Map kinases. 
Therefore, we suggest that CKD-712 might have a role as an 
immunomodulator.
[Immune Network 2011;11(6):420-423]
Immunomodulation has been an interesting phenomenon 
among immunologists since immunopotentiation could en-
hance immunity against infection or tumors, whereas im-
munosupression or anti-inflammatory manipulation can be 
used to control autoimmunity or diseases caused by aberrant 
or hyper-reactive immune responses. Sepsis is caused by hy-
per-responsiveness of the immune system, in which the mor-
tality rate is as high as 50% (1). In septic conditions, large 
amount of pro-inflammatory cytokines is produced rapidly. 
Therefore, the early innate response of the immune system 
to pathogens plays a critical role in septic conditions. Toll-like 
receptors (TLRs) are important pattern recognition receptors 
(PRRs) that participate in the innate immune response. TLR4, 
in conjunction with CD14, acts as the receptor for lip-
opolysaccharide (LPS), a component of Gram-negative bac-
teria cell walls (2). TLR2 recognizes peptidoglycan and lip-
oteichoic acid (LTA) in Gram-positive bacteria cell walls (3). 
Activation of TLR2 or TLR4 through binding of their ligands 
leads to NF-κB activation and transcription of many genes, 
including typical pro-inflammatory cytokines such as tumor 
necrosis factor-α (TNF-α), interleukin- 1 (IL-1), and IL-6 as 
well as several chemokines that recruit leukocytes into the 
site of inflammation (4,5). 
  CKD-712 has been developed as an anti-inflammatory 
agent targeting sepsis. CKD-712 is a higenamine derivative 
(1-alpha-naphthylmethyl-6,7-dihydroxy-1,2,3,4-tetrahydroiso-
quinoline), also referred to as YS 49. It has been shown that 
CKD-712 reduced NO production in macrophage cells and in-
creased survival rates in mice after LPS treatment (6,7). 
Furthermore inhibition of the Janus activated kinase (JAK)-2/ 
signal transducer and activators of transcription (STAT)-1 
pathway by CKD-712 has been reported to decrease levels 
of iNOS, cyclooxygenase-2, and hemeoxygenase-1 in macro-
phage cells (8). More recently, CKD-712 was found to sup-
press the secretion of high-mobility group box 1 (HMGB-1) 
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Figure 1. Effect of CKD-712 on TLR4 signaling. (A) To assess CKD-712 
toxicity HEK293-TLR4 cells (2×105) were cultured with CKD-712 for 
24 hrs and cell viability was determined by MTT assay. (B) To 
evaluate the effect of CKD-712 on NF-κB activation 2×105 HEK-TLR4
cells/well were seeded in 12-well plates and were cultured for 2 days. 
Then NF-κB promoter and pCMV β-gal vector were co-transfeceted 
overnight and CKD-712 (50μM) was pre-treated before LPS 
treatment. LPS was treated for 6 hrs. After measuring luciferase activity 
and β-galactosidase activity the luciferase activity was normalized for
transfection efficiency with the β-galactosidase activity.
CKD-712
Figure 2. Effect of CKD-712 on activation of MAP kinases and IRF3 
in TLR4 signaling. HEK293-TLR4 cells were stimulated with LPS (50 
ng/ml). Western blot was performed anti-ERK, anti-JNK, anti-p38 or 
anti-IRF3 antibodies. CKD-712 (50μM) was pre-treated 1 hr before 
LPS stimulation. Three independent experiments were performed and 
the representative data are shown.
via inhibition of phosphatidylinositol 3 (PI3K)-protein kinase 
C (PKC) signaling after LTA or LPS stimulation in macrophage 
cells (9).
  In this study we attempted to determine which signaling 
pathway is affected by CKD-712 after TLR4 stimulation, since 
TLR4 is the major PRRs responsible in development of sepsis.
  HEK293-TLR4 cells (kindly provided by Professor Douglas 
T. Golenbock, Massachusetts University, USA) were cultured 
in 10% fetal bovine serum-RPMI1640 medium. HEK293-TLR4 
cells express MD2 and CD14 as well. CKD-712 was kindly 
provided by ChongKunDang Pharm, Cheonan. LPS was pur-
chased from Sigma-Aldrich, St. Louis, MI, USA. To assess cell 
viability after treatment of CKD-712, cells were reacted with 
5 mg/ml of tetrazolium salt (3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyltetrazolium bromide, MTT) (Sigma-Aldrich). After 3 
hrs of incubation (37
o
C, 5% CO2) the medium containing MTT 
was removed and 200μl of DMSO was added into the well 
and the absorbance was measured at 540 nm. For the lucifer-
ase assay. 2×10
5
 cells/well were seeded in 12-well plates and 
cultured for 2 days. NF-κB promoter and pCMV β-gal vec-
tor were co-transfected overnight, and CKD-712 was pre-treat-
ed before LPS treatment. LPS was treated for 6 hrs. Luciferase 
activity was measured by a Luciferase Reporter Assay System 
(Promega, Madison, WI, USA) and β-galactosidase activity 
was measured with O-nitrophenyl-β-D-galactopyranoside 
(Sigma-Aldrich), as the substrate. Luciferase activity was nor-
malized for transfection efficiency with the β-galactosidase 
activity. Western blotting was done using anti-TLR4, anti-ERK, 
anti-p38, anti-JNK, anti-IRF3 or anti-Akt antibodies as well as 
control antibodies. All of the antibodies were purchased from 
Cell Signaling Technology (Beverly, MA, USA).
  First, we determined the optimal concentration of CKD-712 
in HEK293-TLR4 cells. When treated with CKD-712 for 24 hrs 
the cell viability was 50% at 100μM and 40% at 200μM (Fig. 
1A). Next, HEK293-TLR4 cells were treated with LPS and NF-
κB activation was measured. CKD-712 was pre-treated 1 hr 
before stimulation of LPS. We found that 50μM of CKD-712 
inhibited NF-κB activation in TLR4 signaling. When treated 
with 50μM of CKD-712, NF-κB activation decreased to less 
than 100,000 RIU (25 ng/ml of LPS) and 200,000 RIU (50 
ng/ml of LPS) when compared to 200,000 RIU and 500,000 
RIU, respectively in control groups (Fig. 1B).
  Next, we investigated whether treatment with CKD-712 
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Figure 3. Effect of CKD-712 on Akt 
activation in TLR4 signaling. HEK293-
TLR4 cells were stimulated with LPS
(50 ng/mL) and western blot was 
performed with anti-Akt antibodies. 
CKD-712 (50 or 100μM) was pre- 
treated 1 hr before LPS stimulation. 
Two independent experiments were
performed and the representative 
data are shown. The density was 
measures by densitometry and 
relative ratio of p-Akt/Akt in study 
groups was calculated based on the
p-Akt/Akt of control group as 1.0.
modulates MAP kinaseactivation. After stimulation with LPS, 
CKD-712 did not inhibit activation of ERK, JNK or p38 kinase 
in HEK293-TLR4 cells (Fig. 2). Rather, pre-treatment with 
CKD-712 delayed activation of these kinases. As shown in 
Fig. 3, MAP kinases were phosphorylated 15∼30 min follow-
ing stimulation with LPS, after which activation subsided in 
60 min. However, CKD-712 treatment extended the activation 
of ERK and JNK, which were found to be activated 60 min 
after TLR4 stimulation (Fig. 2). Phosphorylation of IRF3 was 
not inhibited and showed a sustained activation like the MAP 
kinases (Fig. 2). Interestingly, the activation of Akt was aug-
mented slightly with pre-treatment of CKD-712 (50μM) after 
LPS stimulation (Fig. 3, left). But higher concentration of 
CKD-712 (100μM) inhibited the activation of Akt completely 
(Fig. 3, right). 
  With the brief data presented here, we suggest that 
CKD-712 activated Akt and MAP kinases after TLR4 stim-
ulation at 50μM. Emerging evidence has shown the ex-
istence of a close relation between TLRs and the PI3K/Akt 
pathway. One of the early evidences demonstraetd that 
PI3-kinase is involved in TLR4-mediated cytokine expression 
in mouse macrophages (10). Even in non-immune cells, such 
as, in foam cells, binding of LPS and TLR4 increases Nox1 
expression through the phospholipase A2 β-Akt signaling 
pathway (11). Another paper reporting that HMGB-1 induced 
migration of vascular smooth muscle cells in the TLR4-depen-
dent PI3K/Akt pathway also suggests a strong involvement of 
PI3K/Akt in the TLR4 signaling pathway (12). 
  But the PI3K-Akt-mTOR-p70 S6k pathway is also known to 
be a negative regulator of MyD88-dependent intracellular sig-
nals after TLR stimulation. TLR4-mediated signaling leads to 
rapid activation of PI3K and phosphorylation of Akt, a down-
stream target of PI3K in mouse macrophages, in which the 
sustained interaction of MyD88/PI3K with the TLR4 intra-
cellular “signaling platform” negatively regulates further 
MyD88 dependent signaling (13). The administration of the 
TLR2 ligand, Pam3CSK4, was found to significantly increase 
the levels of phosphorylation of Akt, which lead to significant 
protection in a cerebral injury model, suggesting that the PI3 
kinase-Akt pathway is involved with TLR2 signaling as well 
as TLR4 signaling (14). More recently the association of en-
dogenous TBK1 and Akt was observed in macrophages when 
stimulated with poly (I：C) and LPS, showing that Akt activa-
tion mediated by TBK1 contributes to TLR3 and TLR4-medi-
ated immune responses (15). 
  The effect of CKD-712 on phosphorylation of Akt depends 
on the cell types. In immune cells, CKD-712 inhibits Akt acti-
vation in macrophages (9) and human endothelial cells (15). 
But in rat heart muscle cells, CKD-712 enhances Akt activa-
tion to prevent myocardical ischemia and further inflam-
mation (16). Our data show that in HEK293 cells, CKD-712 
at low concentration augments the activation of Akt, whereas 
high concentration of CKD-712 has an inhibiting effect. 
Therefore pharmaceutical agents regulating the PI3-Akt path-
way may be used as immunomodulators in the innate im-
mune response. Although the mechanism of the augmented 
activation of Akt by CKD-712 and the inhibition of NF-κB 
activation have yet to be clarified, CKD-712 still has a poten-
tial as an immunomodulator. 
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